European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
Chachuat
A
A
Laboratoire Guerbet, Roissy Charles-de-Gaulle, Frankreich.
Bonnemain
B
B
D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003287:Contrast Media / Q000009:adverse effects; D003911:Dextrans; D005060:Europe; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron / Q000009:adverse effects; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000556:secondary; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D010087:Oxides / Q000009:adverse effects; D012680:Sensitivity and Specificity
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide